DEA Registration

DEA Registration Attorney FOR Medical Marijuana OPERATORS.

DEA Registration Application Services

THE 60-DAY WINDOW IS OPEN

Priority filing window. Schedule III rescheduling triggered a 60-day priority registration window for state-licensed medical marijuana operators under 21 C.F.R. § 1301.13(k). Applications filed during this window receive priority processing (six-month decision target) and conditional operating authority during pendency. Applications filed after June 27 go into the standard queue, with no priority processing and no conditional operating authority. It remains unclear how DEA will treat operators who continue medical activity without registering at all.

To Discuss Eligibility:

If you operate a state-licensed medical dispensary, cultivation facility, manufacturer, or vertically integrated operation, this window matters. Call or text 916-572-6445, send an email to Ryan@Kocotlaw.com, or click the button to schedule a consultation.

Schedule A Consultation

WHAT § 1301.13(k) DOES

On April 28, 2026, the Acting Attorney General published AG Order No. 6754-2026, 91 Fed. Reg. 22714, rescheduling FDA-approved marijuana drug products and marijuana subject to a state medical marijuana license from Schedule I to Schedule III of the Controlled Substances Act. The same order created an expedited federal registration pathway at 21 C.F.R. § 1301.13(k) for state-licensed medical marijuana operators.

The pathway provides five things that didn’t exist before:

  • A federal registration category that matches state-licensed medical activity. Under § 1301.13(k)(1), state-licensed operators can register as manufacturers, distributors, or dispensers. A single entity may hold multiple categories.
  • State licenses as conclusive evidence of state authorization. Under § 1301.13(k)(2), a current state medical marijuana license is “conclusive evidence” that the applicant is authorized under state law to engage in the licensed activity. DEA cannot revisit the state determination.
  • State recordkeeping accepted to the maximum extent permissible. Under § 1301.13(k)(4), state-required reports, records, and forms are accepted in lieu of federal versions wherever federal statutory and treaty obligations permit. METRC and equivalent state track-and-trace systems handle most of the inventory recordkeeping work.
  • Conditional operating authority during pendency. Under § 1301.13(k)(7), applicants who file within the 60-day window “may engage in the manufacture, distribution, and/or dispensing of marijuana or products containing marijuana for medical purposes in conformity with a state-issued license” while the application is pending.
  • End of § 280E for state-medical-licensed activity. Section 280E of the Internal Revenue Code disallows ordinary business deductions for Schedule I and II traffickers. Schedule III placement removes state-licensed medical marijuana from the prohibition prospectively. The economic significance for many operators is substantial. The AG Order encourages but does not require Treasury to consider retrospective relief for prior tax years.

The flipside: registration ties federal authorization to state authorization. Under § 1301.13(k)(3), DEA registration automatically suspends when the state license is suspended, revoked, or expires. Federal scope cannot exceed state scope.

WHO NEEDS A DEA REGISTRATION ATTORNEY

State-licensed medical marijuana operators considering or required to pursue federal DEA registration under § 1301.13(k):

  • Dispensaries and retailers. State-licensed medical marijuana retailers can register federally to dispense Schedule III marijuana products under § 1301.13(k)(1)(iii).
  • Cultivators. Cultivation operations register as manufacturers under § 1301.13(k)(1)(i), with cultivation-area designation required under § 1301.13(k)(6)(iii) and Article 23 compliance under § 1301.13(k)(6)(i)-(ii).
  • Manufacturers. Extraction, infusion, processing, packaging, and labeling operations register as manufacturers, with Article 23 obligations where applicable.
  • Distributors. Operations moving marijuana between registered licensees register as distributors under § 1301.13(k)(1)(ii).
  • Vertically integrated operators. Multiple registration categories may be required — manufacturer plus distributor plus dispenser — depending on which licensed functions handle medicinal product.

WHAT WE HANDLE IN A DEA REGISTRATION ENGAGEMENT

End-to-end, not just the form. A DEA registration application is a regulated filing under 21 C.F.R. Part 1301, and the form itself is the smallest part of the registration process. The work that determines whether the application is approved happens before submission.

  • Eligibility analysis under 21 U.S.C. § 823(e)-(g). Confirming registration category, identifying disqualifying criminal history or prior registration issues, and verifying state license alignment. Federal 5%-or-greater ownership disclosure is broader than most state thresholds and requires reconciliation at intake.
  • Operational records review against 21 C.F.R. Part 1304 expectations. DEA expects supporting documentation handling SOPs, inventory controls, employee screening procedures, and security systems consistent with federal standards. We review what you have, identify gaps, and prepare what’s missing before filing.
  • Public-interest analysis under § 823 factors. The substantive standard for approval is whether registration is consistent with the public interest. Manufacturer applicants face § 823(e) factors. Distributor applicants face § 823(f) factors. Dispensers face § 823(g) factors. Each registration type carries a different evidentiary record.
  • Application preparation and filing. Form 224 (manufacturers), Form 225 (distributors), or Form 224 (dispensers) preparation; supporting document compilation; fee payment ($3,699 annual for manufacturers; $1,850 annual for distributors; $888 per three-year cycle for dispensers); and electronic filing through DEA’s diversion control system. Filed correctly the first time, so it doesn’t bounce back for amendments.
  • Article 23 compliance for manufacturers under § 1301.13(k)(6). Cultivation-area designation, nominal-price purchase-and-resale mechanism implementation, and storage-facility access compliance. Article 23 obligations are new to most state-licensed cultivators and require careful pre-application planning.
  • Federal compliance mapping post-registration. Once registered, you’re subject to 21 C.F.R. Part 1304 recordkeeping, Part 1301 security requirements, Part 1302 labeling (modified by § 1301.13(k)(8) state-law-sufficient rules with 21 U.S.C. § 825(c) warning preservation), Part 1317 disposal (modified by § 1301.13(k)(9)), Single Convention quota requirements for some manufacturer categories, and DEA inspection authority. We map operations against these requirements and identify what needs to change before the first DEA inspection.
  • Post-registration support. Registration renewals; amendments for location, ownership, or schedule changes; inspection preparation; and Federal Status Change advisories when state-level changes affect federal registration.

WHAT THE RULE DOES NOT DO

The April 2026 order is significant but limited:

  • Does not legalize adult-use cannabis federally. Adult-use marijuana remains Schedule I. Operators with both M and A designations register only for the medicinal portion.
  • Does not authorize interstate cannabis transfer. State-line movement requires separate compliance with 21 U.S.C. §§ 951-971 and the import/export permit requirements added to 21 C.F.R. § 1312.30(b)-(d).
  • Does not automatically convert a state license into a DEA registration. Federal registration must be applied for, granted, and maintained.
  • Does not extend Schedule III to bulk marijuana outside FDA-approved products or state-medical-licensed activity. Material outside those two categories remains Schedule I.
  • Does not protect activity outside the state license. Federal registration scope cannot exceed state license scope under § 1301.13(k)(3).
  • Does not eliminate federal labeling requirements categorically. State-law labeling is accepted under § 1301.13(k)(8), but the warning required by 21 U.S.C. § 825(c) must appear where applicable.
  • Does not eliminate 18 U.S.C. § 1001 false-statement exposure. Every federal application is sworn under penalty of federal criminal liability for false statements.
  • Does not deliver retroactive § 280E relief. The AG Order encourages Treasury to consider it. Treasury has not promulgated retrospective guidance.

REACH OUT AT (916) 572-6445 OR BOOK A FREE CONSULTATION

A short eligibility call typically identifies the right registration categories, the state-license issues to address before filing, and the documents to gather. No charge for the initial conversation.

Book a Free Consultation:

Call or text 916-572-6445, send an email to Ryan@Kocotlaw.com, or click the button to schedule a consultation.

Schedule A Consultation

STATE-SPECIFIC GUIDANCE

DEA registration is a federal matter. State of operation does not determine whether Kocot Law can represent you on the federal filing — we file applications for operators in any state. State context, however, drives the analysis: the M/A bifurcation problem in California, the vertically-integrated RO structure in New York, the MTC co-location pattern in Massachusetts, and the medical-only enforcement posture in states like Oklahoma each create different federal-application questions.

FREQUENTLY ASKED QUESTIONS

What happens if I miss the priority window?

The pathway remains available. You lose priority processing and conditional operating authority during pendency. Standard DEA processing timelines apply (typically eight to sixteen weeks, sometimes longer for complex applications). Operators who file after June 27 should plan for activity exposure during the application period and should not rely on the § 1301.13(k)(7) conditional operating authority that priority filers receive.

Can I keep operating during the application review?

If you file within the 60-day window, yes — for activity within the scope of your state-issued license. Section 1301.13(k)(7) provides conditional operating authority during pendency. The authority does not extend to adult-use activity on the same premises, does not authorize interstate transfer, and does not extend to applications filed after the window closes.

Does DEA registration allow interstate cannabis shipments?

No. Interstate movement requires separate compliance with 21 U.S.C. §§ 951-971 and import/export permits under 21 C.F.R. § 1312.30(b)-(d). The April 2026 order added marijuana subject to a state medical marijuana license to the permit-required list. Registration under § 1301.13(k) does not include interstate transfer authority.

What is the Article 23 nominal-price mechanism for manufacturers?

Under § 1301.13(k)(6), each registered manufacturer establishes a nominal price for marijuana crops, DEA purchases the crops at that price, and DEA sells them back to the manufacturer (or a related entity) at the same price plus an administrative fee calculated under 21 C.F.R. § 1318.06(a). The mechanism satisfies the Single Convention on Narcotic Drugs requirement that a government agency monopolize the wholesale trade in cannabis. Operationally it is a paper transaction, but it requires registration, fee payment, recordkeeping, and storage-facility access for DEA inspection.

Does Schedule III apply to my adult-use operations?

No. Adult-use marijuana remains Schedule I. Operators with both medicinal and adult-use designations register only for the medicinal portion of the operation. Adult-use activity continues under state law without federal Schedule III protection, and § 280E continues to apply to adult-use revenue.

Will § 280E be retroactive?

The AG Order encourages Treasury to consider retrospective relief. Treasury has not promulgated retrospective guidance. Operators should not plan finances based on retrospective § 280E relief that has not been issued. Prospective relief applies to state-medical-licensed activity from the rule’s effective date forward.

AUTHORITIES AND SOURCES

have questions?

reach out AT (916) 572-6445 OR BOOK a FREE CONSULTATION BELOW.

FrEe CONSULTATION
Scroll to Top